Companies in #Diabetic Macular Edema

Ollin Biosciences is a clinical-stage ophthalmology company developing a next-generation anti-VEGF challenger to Regeneron's Eylea and Roche's Vabysmo for retinal disease. The company raised a $330M Series B in 2026 to fund pivotal Phase 3 trials of its lead asset.